The global oral solid dosage pharmaceutical formulation market was valued at USD 654.6 Mn in 2023 and is projected to grow steadily over the forecast period. The industry is expected to expand at a CAGR of 5.2% from 2024 to 2034, reaching USD 1.1 Bn by the end of 2034. Growth in the market is driven by increasing demand for convenient drug delivery formats such as tablets and capsules, rising pharmaceutical R&D activities, and the expanding global burden of chronic diseases.

Raw material security and the adoption of continuous manufacturing play a critical role. For pharmaceutical manufacturers, maintaining a stable supply of excipients and active pharmaceutical ingredients (APIs) is essential as demand increases. Beyond traditional tablets, other formats are being explored, including mini-tablets, orally disintegrating films (ODFs), and 3D-printed pills. Increasing demand for precision medicine is driving the need for advanced coating technologies and specialized release profiles to reduce dosing frequency.

Dive Deeper into Data: Get Your In-Depth Sample Now! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=80675

With the advancement of nanotechnology and material science, OSD products with improved bioavailability for poorly soluble drugs have been developed. To meet specific therapeutic challenges, innovations such as multi-particulate systems and fixed-dose combinations (FDCs) have been introduced. The rising prevalence of cardiovascular and metabolic disorders has prompted formulations that bundle multiple APIs into a single dosage form to enhance adherence.

Next-generation OSDs may be possible with smart pills and digital integration. In addition to providing controlled release, these technologies allow for real-time monitoring of patient adherence. As continuous manufacturing comes closer to universal adoption, research is focused on overcoming scale-up challenges for complex generics. The transition toward a more efficient manufacturing model is driven by the need to mitigate drug shortages and reduce operational costs.

Key Findings of the Market Report

• Based on dosage form, tablets dominated the market in 2024, accounting for approximately 68% of the total revenue.
• A greater emphasis on controlled-release mechanisms is likely to create high-value opportunities for manufacturers in the oncology and CNS sectors.
• The Asia Pacific region is projected to be the fastest-growing market, driven by expanding manufacturing hubs in China and India.
• Demand for contract development and manufacturing organizations (CDMOs) is surging as small biotech firms outsource complex OSD formulation tasks.

Global OSD Pharmaceutical Formulation Market: Growth Drivers

• Rising Chronic Disease Prevalence: The global increase in hypertension, diabetes, and cancer drives the demand for reliable and stable oral medications.
• Technological Advancements: Innovations like 3D printing and hot-melt extrusion allow for tailored dosing and faster development cycles.
• Aging Global Population: The geriatric demographic prefers OSD forms like chewable tablets and granules due to ease of swallowing and administration.
• Patent Cliffs & Generic Entry: As major blockbuster drugs lose patent protection, the market for generic OSD formulations expands rapidly.
• Focus on Patient Adherence: Advanced taste-masking and aesthetic modifications (color/shape) are being utilized to improve pediatric and geriatric compliance.

Global OSD Pharmaceutical Formulation Market: Regional Landscape

• North America remains the largest market, supported by high R&D investment and a sophisticated healthcare infrastructure. The US FDA’s push for continuous manufacturing and domestic production of essential medicines is a key local driver.
• Asia Pacific is expected to lead in terms of growth rate. Government incentives for generic drug production and the rise of local CDMOs in the region are significant contributors. The growing middle-class population and increased healthcare spending in emerging economies further bolster market demand.

Buy this Premium Research Report:  https://www.transparencymarketresearch.com/checkout.php?rep_id=80675&ltype=S

Global OSD Pharmaceutical Formulation Market: Key Players

Major pharmaceutical and formulation specialists are utilizing organic and inorganic growth strategies to expand their portfolios.

• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• Catalent, Inc.
• Lonza Group AG
• Thermo Fisher Scientific
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Sanofi

Key Developments

• In February 2024, the World Health Organization (WHO) projected a significant rise in cancer cases, triggering a surge in R&D for oncology-specific oral formulations.
• In March 2024, Roquette Freres acquired IFF Pharma Solutions for $2.85 billion to strengthen its position in the pharmaceutical excipients and OSD formulation market.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com     
Email: sales@transparencymarketresearch.com